This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Aventis Pasteur Limited. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: Jim Tartaglia: Innovator in Reverse Transcriptase Detection
Introduction
Jim Tartaglia is a notable inventor based in North York, Canada. He has made significant contributions to the field of biotechnology, particularly in the detection of reverse transcriptase activity in eukaryotic cell lines. His work is crucial for ensuring the safety of biological products, including viral vaccines.
Latest Patents
Tartaglia holds a patent for the "CoRT-PCR assay for the discrimination of endogenous reverse transcriptase activity in eukaryotic cell lines from infectious retrovirus contamination." This invention relates to a method for detecting reverse transcriptase enzymatic activity, which is essential for distinguishing between endogenous and exogenous sources of this activity in cell lines used for manufacturing biological products.
Career Highlights
Throughout his career, Jim Tartaglia has been associated with Aventis Pasteur Limited, where he has applied his expertise in biotechnology. His innovative approach has led to advancements in the safety and efficacy of viral vaccines.
Collaborations
Tartaglia has collaborated with esteemed colleagues such as Scott J Goebel and Maurice Harmon. These partnerships have further enhanced the impact of his work in the field of biotechnology.
Conclusion
Jim Tartaglia's contributions to the detection of reverse transcriptase activity represent a significant advancement in biotechnology. His innovative patent and collaborations underscore his commitment to improving the safety of biological products.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile